vTv Therapeutics (VTVT) Accounts Payables (2014 - 2026)

vTv Therapeutics has disclosed Accounts Payables across 13 years of filings, most recently posting $7.0 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 34.05% year-over-year to $7.0 million; the TTM figure through Jun 2026 stood at $7.0 million (up 34.05% YoY), while the FY2025 annual figure was $6.6 million, up 30.44% from the prior year.
• Accounts Payables came in at $7.0 million for Q2 2026 at vTv Therapeutics, up from $6.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $12.5 million in Q1 2022 to a low of $4.2 million in Q1 2025.
• Average Accounts Payables over 5 years is $7.8 million, with a median of $7.2 million recorded in 2022.
• Year-over-year, Accounts Payables jumped 151.24% in 2022 and plunged 52.0% in 2025.
• Over 5 years, Accounts Payables stood at $7.3 million in 2022, then surged by 40.05% to $10.2 million in 2023, then tumbled by 50.92% to $5.0 million in 2024, then jumped by 30.44% to $6.6 million in 2025, then grew by 6.63% to $7.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $7.0 million in Q2 2026, $6.8 million in Q1 2026, and $6.6 million in Q4 2025.